"Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

February 14, 2020

Primary Completion Date

December 13, 2023

Study Completion Date

December 13, 2023

Conditions

Peripheral T Cell LymphomaPediatric Hodgkin Lymphoma

Interventions

DRUG

Brentuximab Vedotin (Genetical Recombination)

Brentuximab Vedotin Intravenous Infusion

Trial Locations (1)

Takeda Selected Site, Tokyo